Evaluation of the Effectiveness of Additional Risk Minimisation Measures for Tofacitinib (Xeljanz®) in Europe: A Prescriber Survey
Authors
- Krystal Cantos (ORCID: https://orcid.org/0000-0003-4216-3273)
- Joanne Wu
- Nana Koram (ORCID: https://orcid.org/0000-0002-4890-6202)
- Edward Nagy
- Laura Walsh (ORCID: https://orcid.org/0000-0002-8128-2980)
- Rafia Bosan (ORCID: https://orcid.org/0000-0003-4226-6715)
- Lubna Merchant (ORCID: https://orcid.org/0000-0001-8891-287X)
- Kofi Asomaning
- Robert Massouh (ORCID: https://orcid.org/0000-0001-6079-1869)
- Subhan Khalid
Institutions
- Pfizer (United States) (US)
- IQVIA (United States) (US)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1007/s40261-024-01408-5
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00